A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

No matter how you get Zepbound ... Food and Drug Administration. Zepbound label. Eli Lilly. How much should I expect to pay for Zepbound (tirzepatide)?. Food and Drug Administration.

This is a one-time financial adjustment related to accounting that has no bearing on ... often prescribed off-label for any type of weight loss. During the quarter, Zepbound became the market ...

In the first quarter, top-line growth is expected to have been driven by demand growth for Lilly’s FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine ...

Unlike others in its class, tirzepatide targets two hormones — glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This double action makes it particularly ...

In a statement, Ro said it will make Zepbound available as a treatment option with an on-label prescription from ... manager CVS Health said it would no longer cover its weight-loss therapy ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

Caissa Troutman, MD, recently treated a patient in her early 50s who she planned to prescribe the anti-obesity medication Zepbound ... “morbid obesity” is no longer acceptable and is not ...